2021
Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial
Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Akhondzadeh S, Bozorgi A. Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial. IJC Heart & Vasculature 2021, 34: 100789. PMID: 34027030, PMCID: PMC8129927, DOI: 10.1016/j.ijcha.2021.100789.Peer-Reviewed Original ResearchPre-syncopal episodesRecurrent vasovagal syncopeVasovagal syncopeEffects of atomoxetinePrimary endpointPlacebo groupMedian timeSubgroup analysis of patientsPre-syncopal attackNorepinephrine reuptake inhibitionPlacebo-controlled trialAnalysis of patientsPharmacological treatment optionsSystolic blood pressureDiagnosed VVSSyncope/pre-syncopeReduced quality of lifeReuptake inhibitionRandomized patientsAtomoxetine groupSyncopal episodesVasovagal attackTreatment optionsSubgroup analysisRandomized trials
2017
Combined HMG-COA reductase and prenylation inhibition in treatment of CCM
Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A, Louvi A, Gunel M. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 5503-5508. PMID: 28500274, PMCID: PMC5448170, DOI: 10.1073/pnas.1702942114.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAstrocytesDiphosphonatesDrosophilaDrug Evaluation, PreclinicalDrug Therapy, CombinationEndothelial CellsFatty Acids, MonounsaturatedFemaleFluvastatinHemangioma, Cavernous, Central Nervous SystemHigh-Throughput Screening AssaysHydroxymethylglutaryl-CoA Reductase InhibitorsImidazolesIndolesMaleMAP Kinase Signaling SystemMicePregnancyProtein PrenylationZoledronic AcidConceptsCerebral cavernous malformationsTreatment of CCMsCommon vascular anomaliesPotential pharmacological treatment optionsFocal neurological deficitsPharmacological treatment optionsCCM diseaseAcute mouse modelCentral nervous systemNeurological deficitsHemorrhagic strokePharmacological therapyLesion burdenVascular deficitsSymptomatic lesionsCombination therapyTreatment optionsVascular anomaliesGlial cellsCavernous malformationsMouse modelPrimary astrocytesNervous systemDrug AdministrationSustained inhibitionPharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions
Hassell C, Wilkins K, Trevisan L. Pharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions. Current Treatment Options In Psychiatry 2017, 4: 102-115. DOI: 10.1007/s40501-017-0107-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSubstance use disordersEvidence-based treatmentsUse disordersGeriatric populationEvidence-based pharmacological treatment optionsAvailable evidence-based treatmentsHigh-quality clinical trialsOlder adultsAvailable pharmacological treatmentsPharmacological treatment optionsLimitations of treatmentPharmacological treatmentTreatment optionsClinical trialsCertain drugsYoung adultsAdverse effectsDisordersTreatmentAdultsHigh rateUnique needsPopulationBaby boomer generationDysfunction
2015
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatment
2013
A 66-Year-Old Woman with Facial Tics and Social Impairment
Garakani A, Welch A, Newcorn J. A 66-Year-Old Woman with Facial Tics and Social Impairment. Psychiatric Annals 2013, 43: 10-14. DOI: 10.3928/00485713-20130109-03.Peer-Reviewed Case Reports and Technical NotesAttention-deficit/hyperactivity disorderHyperactivity disorderCognitive behavioral therapyAttention problemsInterpersonal functioningSocial impairmentOlder adultsPsychopharmacologic interventionsSelf-reported historyPharmacological treatment optionsEducational objectivesAdultsInattentionOlder patientsDisordersTreatment optionsMedical historyMedication managementDifferential diagnosisOlder womenFacial ticsFunctioningWhite womenDeficitsPsychiatrists
2012
Enhancing informed consent best practices: gaining patient, family and provider perspectives using reverse simulation
Goldfarb E, Fromson JA, Gorrindo T, Birnbaum RJ. Enhancing informed consent best practices: gaining patient, family and provider perspectives using reverse simulation. Journal Of Medical Ethics 2012, 38: 546. PMID: 22522147, DOI: 10.1136/medethics-2011-100206.Peer-Reviewed Original ResearchConceptsHealthcare providersInformed consentPharmacological treatment optionsAtypical antipsychotic medicationsInformed consent discussionAdverse eventsAntipsychotic medicationTreatment optionsCollaborative carePatient retentionTherapeutic effectPsychotic symptomsClinical practicePatientsConsent discussionPatient careClinical settingProvider perspectivesPreventative measuresConsent processMedicationsDoctors' performanceFamily membersExpressed needsCareCurrent and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals
Tetrault JM, Fiellin DA. Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals. Drugs 2012, 72: 217-228. PMID: 22235870, PMCID: PMC3701303, DOI: 10.2165/11597520-000000000-00000.Commentaries, Editorials and LettersConceptsOpioid dependenceMaintenance treatmentDrug useHepatitis C virus transmissionOpioid agonist maintenanceOpioid agonist medicationsPotential pharmacological treatment optionsC virus transmissionPharmacological treatment optionsInjection drug useOpioid-dependent individualsDirect healthcare costsIllicit opioid usersHIV risk behaviorsGlobal economic burdenIllicit drug useTerms of HIVSustained-release formulationMaintenance therapyAgonist medicationsOpioid antagonistAgonist maintenanceTreatment optionsOpioid usersImproved outcomes
2004
Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations
Smith-Rohrberg D, Bruce R, Altice F. Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. Journal Of Drug Issues 2004, 34: 451-480. DOI: 10.1177/002204260403400210.Peer-Reviewed Original ResearchOpiate dependencePharmacological treatment optionsEmergency room usePrimary care servicesOpiate-dependent patientsCommunity-based treatmentInfectious disease prevalenceBuprenorphine treatmentNote reviewTreatment optionsOpiate useCorrectional populationsDrug AdministrationRecent approvalCare servicesDisease prevalenceRoom useSubstantial proportionTreatmentCorrectional settingsDesirable healthBuprenorphinePatientsTherapyPopulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply